AbbVie Reports Topline Results From Phase 3 INTREPID Study Evaluating Lutikizumab, Investigational Dual-Variable-Domain IL 1α/1β Antagonist, In Hidradenitis Suppurativa; Study Met Primary Endpoint And 8 Ranked Secondary Endpoints — последние новости